EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Innovative approach in malaria research: Harnessing CRISPR-Cas9 for antimalarial drug-resistance studies in Africa

Olusola Ajibaye, Idowu Samuel Dada, Haddijatou Mbye, Ikechukwu Chidiebere Nwankwo, Eniyou Oriero, Alfred Amambua-Ngwa

Molecular Therapy · 2026

DOI: 10.1016/j.ymthe.2025.12.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2026. Verfasst von Olusola Ajibaye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria; Medical Research Council at the London School of Hygiene and Tropical Medicine, Banjul,…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Antimalarials, Drug Resistance, Plasmodium falciparum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria remains a major global health challenge, particularly in sub-Saharan Africa, where Plasmodium falciparum is increasingly resistant to frontline antimalarial therapies. CRISPR-Cas9, a groundbreaking genome editing tool, has become a transformative force in biomedical research, offering valuable insights into the genetic mechanisms underlying drug resistance. This review provides a comprehensive overview of the CRISPR-Cas9 system, its origin, evolution, and application in antimalarial drug-resistance research, with particular emphasis on African studies. We examine the role of CRISPR in elucidating resistance pathways, validating molecular markers, and enhancing diagnostic strategies. Additionally, a systematic scoping review highlights the geographic scope and focus of CRISPR-related malaria research conducted across Africa. Significantly low application and adoption were observed. Despite existing technological and regulatory barriers, CRISPR holds strong potential for accelerating antimalarial drug discovery and advancing precision medicine. Its strategic application in malaria-endemic regions could significantly bolster efforts toward disease control and eventual elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsAntimalarialsDrug ResistancePlasmodium falciparumMalariaHumansGene EditingAfricaAnimalsMalaria, Falciparum

Stichwörter der Autor:innen

CRISPR-Cas9Plasmodium falciparumantimalarialdrug resistancegene editing

Substanzen

Antimalarials

Autor:innen und Institutionen

  • Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria; Medical Research Council at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia; Eko University of Medicine and Health Sciences, Lagos-Bad…
  • Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
  • Medical Research Council at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.
  • Drexel University College of Medicine, Philadelphia, PA, USA.

Zitieren

APA

Ajibaye, O., Dada, I. S., Mbye, H., Nwankwo, I. C., Oriero, E., & Amambua-Ngwa, A. (2026). Innovative approach in malaria research: Harnessing CRISPR-Cas9 for antimalarial drug-resistance studies in Africa. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.12.034

Vancouver

Ajibaye O, Dada IS, Mbye H, Nwankwo IC, Oriero E, Amambua-Ngwa A. Innovative approach in malaria research: Harnessing CRISPR-Cas9 for antimalarial drug-resistance studies in Africa. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2025.12.034

BibTeX
@article{Ajibaye2026,
  author = {Ajibaye, Olusola and Dada, Idowu Samuel and Mbye, Haddijatou and Nwankwo, Ikechukwu Chidiebere and Oriero, Eniyou and Amambua-Ngwa, Alfred},
  title = {Innovative approach in malaria research: Harnessing CRISPR-Cas9 for antimalarial drug-resistance studies in Africa},
  journal = {Molecular Therapy},
  year = {2026},
  doi = {10.1016/j.ymthe.2025.12.034}
}
Kostenlos starten →